









Markets
/
Stocks
/
nasdaq-cntb
/

Connect Biopharma Holdings Ltd

CNTB

1.570USD

-0.040-2.48%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

87.26MMarket Cap

LossP/E TTM



Connect Biopharma Holdings Ltd

1.570

-0.040-2.48%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

230 / 506

Overall Ranking

370 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

6.833

Target Price

+324.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company focused on improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. It is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. Its second product candidate, icanbelimod, is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). Icanbelimod is an orally available, small molecule modulator of S1P1 that is designed to reduce inflammation without killing T cells.

Growing

The company is in a growing phase, with the latest annual income totaling USD 26.03M.

Overvalued

The company’s latest PE is -1.87, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 47.05M shares, decreasing 6.41% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 143.70K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.04.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.92, which is 27.33% below the recent high of -2.44 and -56.64% above the recent low of -3.00.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 230/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Connect Biopharma Holdings Ltd is 7.00, with a high of 7.50 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

6.833

Target Price

+324.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Connect Biopharma Holdings Ltd

CNTB

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.49, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.02 and the support level at 1.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.49

Change

-0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.052

Sell

RSI(14)

40.286

Neutral

STOCH(KDJ)(9,3,3)

11.288

Oversold

ATR(14)

0.167

Low Volatility

CCI(14)

-83.421

Neutral

Williams %R

96.923

Oversold

TRIX(12,20)

-0.748

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.600

Sell

MA10

1.651

Sell

MA20

1.758

Sell

MA50

1.889

Sell

MA100

1.386

Buy

MA200

1.151

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 84.81%, representing a quarter-over-quarter increase of 0.22%. The largest institutional shareholder is James Simons, holding a total of 143.70K shares, representing 0.26% of shares outstanding, with 5.96% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Panacea Venture

13.41M

+11.75%

BioFortune Inc

6.16M

Wei (Zheng)

5.93M

Shanghai Minhui Enterprise Management Consulting Partnership

5.31M

Qiming Venture Partners

4.84M

Advantech Capital II L.P.

4.76M

Lilly Asia Ventures

3.34M

BML Capital Management LLC

2.09M

Szekeres (David Leslie)

160.87K

Choreo, LLC

160.87K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.15, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.11. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.